Subtopic Deep Dive

← Advanced Glycation End Products research

HMGB1 in Diabetic Inflammation
Research Guide

What is HMGB1 in Diabetic Inflammation?

HMGB1 in Diabetic Inflammation examines the release of high-mobility group box 1 from necrotic pancreatic beta cells and its role in amplifying sterile inflammation through TLR4 and RAGE receptors in diabetes.

High-mobility group box 1 (HMGB1) acts as a damage-associated molecular pattern (DAMP) released during hyperglycemia-induced beta cell necrosis, binding RAGE and TLR4 to trigger proinflammatory cascades (Yao and Brownlee, 2009, 509 citations). This process correlates with diabetic complication severity, including vasculopathy and retinopathy. Over 10 key papers from 2004-2020, with 400-1251 citations, link HMGB1-RAGE signaling to diabetic inflammation.

Curated Papers

Key Challenges

Why It Matters

HMGB1 blockade via anti-HMGB1 antibodies reduces inflammation in diabetic models, positioning it as a therapeutic target for vasculopathy (Yang et al., 2020, 601 citations). RAGE deficiency attenuates atherosclerosis in diabetic mice, highlighting HMGB1-RAGE axis inhibition for cardiovascular protection (Soro-Paavonen et al., 2008, 401 citations). In retinopathy, HMGB1 amplifies vascular inflammation, suggesting combined RAGE-HMGB1 therapies to preserve vision (Semeraro et al., 2015, 400 citations).

Key Research Challenges

Quantifying HMGB1 Release

Distinguishing hyperglycemia-induced HMGB1 from necrotic beta cells versus other sources remains difficult. Yao and Brownlee (2009) show ROS upregulate HMGB1 and RAGE, but serum profiling lacks specificity for diabetic inflammation. Over 500 citations confirm need for beta-cell specific assays.

TLR4-RAGE Crosstalk

HMGB1 signals via both TLR4 and RAGE, complicating selective blockade in sterile inflammation. Dumitriu et al. (2005, 497 citations) demonstrate dendritic cell HMGB1 release activates T cells through RAGE. Yang et al. (2020) note multi-faceted HMGB1 functions challenge targeted therapies.

Translating to Complications

Correlating serum HMGB1 with vasculopathy severity requires longitudinal studies. Burke et al. (2004, 492 citations) localize RAGE ligands in diabetic plaques, but clinical trials for HMGB1 inhibitors lag. Sparvero et al. (2009, 615 citations) emphasize RAGE ligands' role in chronic inflammation progression.

Essential Papers

Understanding RAGE, the receptor for advanced glycation end products

Angelika Bierhaus, Per M. Humpert, Michael Morcos et al. · 2005 · Journal of Molecular Medicine · 1.3K citations

Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease

Sebastian Steven, Katie Frenis, Matthias Oelze et al. · 2019 · Oxidative Medicine and Cellular Longevity · 660 citations

Cardiovascular disease is a leading cause of death and reduced quality of life, proven by the latest data of the Global Burden of Disease Study, and is only gaining in prevalence worldwide. Clinica...

RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation

Louis J. Sparvero, Denise Asafu‐Adjei, Rui Kang et al. · 2009 · Journal of Translational Medicine · 615 citations

Abstract The Receptor for Advanced Glycation Endproducts [RAGE] is an evolutionarily recent member of the immunoglobulin super-family, encoded in the Class III region of the major histocompatabilit...

Targeting Inflammation Driven by HMGB1

Huan Yang, Haichao Wang, Jan Andersson · 2020 · Frontiers in Immunology · 601 citations

High mobility group box 1 (HMGB1) is a highly conserved, nuclear protein present in all cell types. It is a multi-facet protein exerting functions both inside and outside of cells. Extracellular HM...

Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of the Receptor for Advanced Glycation End Products (RAGE) and RAGE Ligands

Dachun Yao, Michael Brownlee · 2009 · Diabetes · 509 citations

OBJECTIVE RAGE interacts with the endogenous ligands S100 calgranulins and high mobility group box 1 (HMGB1) to induce inflammation. Since hyperglycemia-induced reactive oxygen species (ROS) activa...

Release of High Mobility Group Box 1 by Dendritic Cells Controls T Cell Activation via the Receptor for Advanced Glycation End Products

Ingrid E. Dumitriu, Paramita Baruah, Barbara Valentinis et al. · 2005 · The Journal of Immunology · 497 citations

Abstract High mobility group box 1 (HMGB1) is an abundant and conserved nuclear protein that is released by necrotic cells and acts in the extracellular environment as a primary proinflammatory sig...

Morphologic Findings of Coronary Atherosclerotic Plaques in Diabetics

Allen Burke, Frank D. Kolodgie, Arthur W. Zieske et al. · 2004 · Arteriosclerosis Thrombosis and Vascular Biology · 492 citations

Objective— Coronary atherosclerotic plaque composition of diabetic subjects and localization of receptor for advanced glycation end products (RAGE) and its ligands have not been extensively studied...

Reading Guide

Foundational Papers

Start with Bierhaus et al. (2005, 1251 citations) for RAGE overview, then Yao and Brownlee (2009, 509 citations) for hyperglycemia-HMGB1 link, followed by Dumitriu et al. (2005, 497 citations) for release mechanisms.

Recent Advances

Study Yang et al. (2020, 601 citations) for HMGB1 targeting; Hudson and Lippman (2017, 473 citations) for RAGE signaling; Semeraro et al. (2015, 400 citations) for retinopathy applications.

Core Methods

Core techniques: RAGE knockout models (Soro-Paavonen et al., 2008); immunohistochemistry for plaque ligands (Burke et al., 2004); ROS assays for ligand upregulation (Yao and Brownlee, 2009).

How PapersFlow Helps You Research HMGB1 in Diabetic Inflammation

Discover & Search

Research Agent uses searchPapers('HMGB1 diabetic inflammation RAGE') to retrieve Yao and Brownlee (2009), then citationGraph reveals 509 citing papers on ROS-HMGB1 links, while findSimilarPapers expands to Soro-Paavonen et al. (2008) for RAGE deficiency in atherosclerosis.

Analyze & Verify

Analysis Agent applies readPaperContent on Yang et al. (2020) to extract HMGB1 blockade mechanisms, verifyResponse with CoVe cross-checks claims against Bierhaus et al. (2005), and runPythonAnalysis plots serum HMGB1 correlations from extracted data using pandas for statistical verification; GRADE scores evidence as high for therapeutic potential.

Synthesize & Write

Synthesis Agent detects gaps in TLR4-RAGE crosstalk from Dumitriu et al. (2005), flags contradictions in ligand specificity, then Writing Agent uses latexEditText for figure captions, latexSyncCitations integrates 10 papers, and latexCompile generates a review manuscript with exportMermaid for HMGB1 signaling diagrams.

Use Cases

"Analyze HMGB1 serum levels vs diabetic retinopathy severity from recent papers"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas correlation plot on extracted data from Semeraro et al. 2015 and Yao 2009) → matplotlib figure of HMGB1-RAGE inflammation trends.

"Write LaTeX review on HMGB1-RAGE in diabetic vasculopathy"

Synthesis Agent → gap detection on Burke et al. 2004 → Writing Agent → latexEditText (structure sections) → latexSyncCitations (add Sparvero 2009 et al.) → latexCompile → PDF with RAGE plaque morphology diagram.

"Find code for simulating HMGB1 release in beta cell necrosis models"

Research Agent → paperExtractUrls (Yao 2009) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow outputs Python simulation script for ROS-induced HMGB1 kinetics.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers('HMGB1 RAGE diabetes') → 50+ papers → citationGraph → structured report on inflammation cascades with GRADE scores. DeepScan applies 7-step analysis with CoVe checkpoints to verify HMGB1 claims in Steven et al. (2019). Theorizer generates hypotheses like 'HMGB1-TLR4 blockade prevents plaque formation' from Burke et al. (2004) and Soro-Paavonen et al. (2008).

Try Doxa for HMGB1 in Diabetic Inflammation Research

Frequently Asked Questions

What defines HMGB1's role in diabetic inflammation?

HMGB1 releases from necrotic beta cells under hyperglycemia, binding RAGE/TLR4 to amplify sterile inflammation (Yao and Brownlee, 2009; Dumitriu et al., 2005).

What are key methods studying HMGB1-RAGE?

Methods include ROS induction assays, RAGE knockout mice, and serum HMGB1 ELISA profiling in diabetic models (Yao and Brownlee, 2009; Soro-Paavonen et al., 2008).

What are foundational papers?

Bierhaus et al. (2005, 1251 citations) on RAGE; Yao and Brownlee (2009, 509 citations) on HMGB1 upregulation; Dumitriu et al. (2005, 497 citations) on DC-HMGB1 release.

What open problems exist?

Selective HMGB1 inhibitors avoiding immunosuppression; longitudinal human trials linking serum HMGB1 to complications; distinguishing TLR4 vs RAGE pathways (Yang et al., 2020).